List of works - Peter Johansson

A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma

scientific article (publication date: 2013)

A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma

scientific article

Assessment of PALB2 as a candidate melanoma susceptibility gene

scientific article

Confirmation of a BRAF mutation-associated gene expression signature in melanoma.

scientific article published on June 2007

Correction to: Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab

scientific article published on 01 July 2019

Detection and identification of protein isoforms using cluster analysis of MALDI-MS mass spectra

scientific article published in April 2006

Development of peptide nucleic acid probes for detection of the HER2 oncogene

scientific article

Differences between acral and nonacral melanoma genomes

scientific article published on 19 November 2019

Expression profiling identifies epoxy anthraquinone derivative as a DNA topoisomerase inhibitor

scientific article

Germline variants in oculocutaneous albinism genes and predisposition to familial cutaneous melanoma

scientific article published on 06 July 2019

Improving missing value imputation of microarray data by using spot quality weights

scientific article published on 16 June 2006

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.

scientific article published on 2 December 2014

Loss-of-function variants in POT1 predispose to uveal melanoma

scientific article published on 09 September 2020

Massively parallel sequencing reveals an accumulation of de novo mutations and an activating mutation of LPAR1 in a patient with metastatic neuroblastoma

scientific article

Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma.

scientific article published on 23 August 2013

Microarray expression profiling in melanoma reveals a BRAF mutation signature.

scientific article published on May 2004

Mutation load in melanoma is affected by MC1R genotype

scientific article published on 26 December 2016

Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma

scientific article

Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN.

scientific article published on 29 March 2006

POLE mutations in families predisposed to cutaneous melanoma

scientific article published on 7 August 2015

POT1 loss-of-function variants predispose to familial melanoma

scientific article

Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.

scholarly article

Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases.

scientific article published on 19 March 2015

Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab

scientific article published on 04 February 2019

Recurrent inactivating RASA2 mutations in melanoma

scientific article published on 26 October 2015

Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma

scientific article

Tumor mutation burden and structural chromosomal aberrations are not associated with T-cell density or patient survival in acral, mucosal, and cutaneous melanomas

scientific article published on 11 September 2020

Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes.

scientific article published on 29 October 2015

microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies.

scientific article published on 25 August 2009

List of works by Peter Johansson

A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma

A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma

Assessment of PALB2 as a candidate melanoma susceptibility gene

Confirmation of a BRAF mutation-associated gene expression signature in melanoma.

Correction to: Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab

Detection and identification of protein isoforms using cluster analysis of MALDI-MS mass spectra

Development of peptide nucleic acid probes for detection of the HER2 oncogene

Differences between acral and nonacral melanoma genomes

Expression profiling identifies epoxy anthraquinone derivative as a DNA topoisomerase inhibitor

Germline variants in oculocutaneous albinism genes and predisposition to familial cutaneous melanoma

Improving missing value imputation of microarray data by using spot quality weights

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.

Loss-of-function variants in POT1 predispose to uveal melanoma

Massively parallel sequencing reveals an accumulation of de novo mutations and an activating mutation of LPAR1 in a patient with metastatic neuroblastoma

Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma.

Microarray expression profiling in melanoma reveals a BRAF mutation signature.

Mutation load in melanoma is affected by MC1R genotype

Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma

Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN.

POLE mutations in families predisposed to cutaneous melanoma

POT1 loss-of-function variants predispose to familial melanoma

Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.

Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases.

Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab

Recurrent inactivating RASA2 mutations in melanoma

Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma

Tumor mutation burden and structural chromosomal aberrations are not associated with T-cell density or patient survival in acral, mucosal, and cutaneous melanomas

Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes.

microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies.